PULSE BIOSCIENCES, INC. — Director's Dealing 2022

Jun 11, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pulse Biosciences, Inc. (PLSE)
CIK: 0001625101
Period of Report: 2022-06-09

Reporting Person: Levinson Mitchell E. (Director, Chief Strategy Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-06-09	Common Stock	X	10935	—	Acquired	37504	Direct
2022-06-09	Common Stock	X	814	—	Acquired	4135	Indirect
2022-06-09	Common Stock	X	143	—	Acquired	734	Indirect
2022-06-09	Common Stock	X	143	—	Acquired	734	Indirect
2022-06-09	Common Stock	X	143	—	Acquired	734	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-09	Warrant (right to buy)	$2.05	P	10935	Acquired	2027-06-09	Common Stock (10935)	Direct
2022-06-09	Warrant (right to buy)	$2.05	P	814	Acquired	2027-06-09	Common Stock (814)	Indirect
2022-06-09	Warrant (right to buy)	$2.05	P	143	Acquired	2027-06-09	Common Stock (143)	Indirect
2022-06-09	Warrant (right to buy)	$2.05	P	143	Acquired	2027-06-09	Common Stock (143)	Indirect
2022-06-09	Warrant (right to buy)	$2.05	P	143	Acquired	2027-06-09	Common Stock (143)	Indirect

Footnotes

F1: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and the Prospectus Supplement and certain Current Reports on Form 8-K filed by the Issuer with the SEC.

F2: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $2.05 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $2.05.